Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    Advancing Transient Passive Immunity for Biothreats

    By Global Biodefense StaffNovember 5, 2012
    Share
    Facebook LinkedIn Reddit Email

    The Defense Advanced Research Projects Agency (DARPA) is seeking innovative methods of scalable passive immunization to protection personnel for a period of time, suitable to a military mission requirement or in a public health setting.  Towards this goal, the agency is soliciting proposals for the development of nucleic acid platforms capable of in vivo host production of a transient immune prophylaxis for adults. 

    The effort is part of the Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats (ADEPT-PROTECT) initiative. The solicitation seeks approaches that deliver nucleic acid constructs to an immunologically naïve host in formats that are by design transient, expressed from reusable platforms (i.e., do not themselves elicit an immune response), and capable of producing the necessary repertoire of antibodies or other immune molecules at levels sufficient for prophylaxis. 

    The DARPA vision is to develop platform technologies that will ultimately enable transferrable immune protection equivalent to the effective component of plasmapheresis or intravenous immunoglobulin that is universal, safe, adaptable, and scalable to protect the US population. The long-term goal will be to rapidly achieve protection or prevent transmission even in instances when the emerging or engineered threat is unknown. 

    The agency is only considering innovative methods to advance beyond current state-of-the art and which address the inherent technical challenges including identification of protective oligoclonal immune responses; design and delivery of nucleic acid constructs to produce and express the oligoclonal response at a protective concentration and clinically-relevant duration; and ensuring safety by demonstrating that the system is non-integrating and transient.

    The effort will develop methodologies that can:

    Offer protection against known diseases or threats where no specific therapeutic or vaccine exists
    Impart robust, yet temporary immune protection to bridge the time gap between the delivery of an existing vaccine and the subsequent development of a protective immune response
    Offer protection against emerging or uncharacterized threats
    Confer protection for a time period greater than a single administration with an existing antibody for passive immunization
    Achieve broad oligoclonal immune protection beyond monoclonal antibody
    Bypass manufacturing challenges associated with rapid design and production of an in vitro monoclonal antibody for passive immunization
    Manufacture at a cost less than in vitro monoclonal antibody therapy and competitive with a cost per dose of vaccine

    Full details are available under Solicitation Number: DARPA-BAA-13-03. Proposal abstracts are due November 29, 2012 with full proposals due no later than January 15, 2013.

    BAA DARPA
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBiodefense News – November 4, 2012
    Next Article Aberdeen Proving Ground Advance Planning Briefing for Industry

    Related Stories

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    Mass Spec for Rapid Detection of Biological Warfare Agents

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy